A Study in Healthy Subjects to Assess the Multiple- Dose Pharmacokinetics of Three AF-219 Formulations
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Gefapixant (Primary) ; Omeprazole
- Indications Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
- Focus Pharmacokinetics
- Sponsors Afferent Pharmaceuticals
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 04 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.